Home
/
CATALYST PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
CATALYST PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that CATALYST PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2020
Sep 30, 2020
$29.32M
Nov 9, 2020
Q3
2020
Sep 30, 2019
$30.90M
Nov 9, 2020
Q1
2019
Mar 31, 2019
$12.45M
May 10, 2019
Q1
2019
Mar 31, 2018
$0
May 10, 2019
Q1
2017
Mar 31, 2017
$0
May 10, 2017
Q1
2017
Mar 31, 2016
$0
May 10, 2017
Q1
2016
Mar 31, 2015
$0
May 10, 2016
Q1
2015
Mar 31, 2014
$0
May 11, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$148.39M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$146.56M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$141.42M
May 7, 2025
Q3
2025
Sep 30, 2024
$128.70M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$122.71M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$98.51M
May 7, 2025
Q3
2024
Sep 30, 2023
$102.69M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$99.58M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$85.37M
May 8, 2024
Q3
2023
Sep 30, 2022
$57.24M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$53.11M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$43.09M
May 10, 2023
Q3
2022
Sep 30, 2021
$35.95M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$36.37M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$30.21M
May 10, 2022
Q3
2021
Sep 30, 2020
$29.32M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$29.61M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$29.14M
May 10, 2021
Q3
2020
Sep 30, 2019
$30.90M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$28.84M
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$52.78M
Nov 5, 2025
Q3
2025
Jun 30, 2025
$52.11M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$52.11M
Aug 6, 2025
Q3
2025
Mar 31, 2025
$56.74M
Nov 5, 2025
Q2
2025
Mar 31, 2025
$56.74M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$56.74M
May 7, 2025
Q3
2025
Sep 30, 2024
$43.88M
Nov 5, 2025
Q3
2025
Jun 30, 2024
$40.79M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$40.79M
Aug 6, 2025
Q2
2025
Mar 31, 2024
$23.28M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$23.28M
May 7, 2025
Q3
2025
Mar 31, 2024
$23.28M
Nov 5, 2025
Q3
2024
Sep 30, 2023
($30.76M)
Nov 6, 2024
Q3
2024
Jun 30, 2023
$37.76M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$37.76M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$29.57M
May 8, 2024
Q3
2024
Mar 31, 2023
$29.57M
Nov 6, 2024
Q2
2024
Mar 31, 2023
$29.57M
Aug 7, 2024
Q3
2023
Sep 30, 2022
$22.75M
Nov 8, 2023
Q3
2023
Jun 30, 2022
$21.62M
Nov 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$66.27M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$66.30M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$63.37M
May 7, 2025
Q3
2025
Sep 30, 2024
$50.91M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$54.25M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$27.13M
May 7, 2025
Q3
2024
Sep 30, 2023
($37.19M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
$46.70M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$35.61M
May 8, 2024
Q3
2023
Sep 30, 2022
$25.10M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$28.57M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$17.37M
May 10, 2023
Q3
2022
Sep 30, 2021
$14.00M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$15.84M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$9.80M
May 10, 2022
Q3
2021
Sep 30, 2020
$11.70M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$10.28M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$10.70M
May 10, 2021
Q3
2020
Sep 30, 2019
$13.85M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$10.96M
Aug 10, 2020